138 related articles for article (PubMed ID: 25702620)
21. Cyclosporine nephrotoxicity: associated allograft dysfunction at low trough concentration.
Jankauskiene A; Druskis V; Laurinavicius A
Clin Nephrol; 2001 Dec; 56(6):S27-9. PubMed ID: 11770808
[TBL] [Abstract][Full Text] [Related]
22. Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity.
Al-Aly Z; Sachdeva A; Philoctete Ashley JM; Bastani B
Nephrology (Carlton); 2006 Apr; 11(2):151-5. PubMed ID: 16669979
[TBL] [Abstract][Full Text] [Related]
23. A case of late onset cyclosporine-induced hemolytic uremic syndrome resulting in renal graft loss.
Katafuchi R; Saito S; Ikeda K; Hirano T; Yanase T; Nakashima K; Fujimi S
Clin Transplant; 1999; 13 Suppl 1():54-8. PubMed ID: 10751058
[TBL] [Abstract][Full Text] [Related]
24. Pantoprazole does not affect cyclosporin A blood concentration in kidney-transplant patients.
Lorf T; Ramadori G; Ringe B; Schwörer H
Eur J Clin Pharmacol; 2000 Jan; 55(10):733-5. PubMed ID: 10663451
[TBL] [Abstract][Full Text] [Related]
25. A nomogram for predicting optimal dosage of cyclosporine in renal transplant patients: taking physiological factors into consideration for regimen during immunosuppressive therapy.
Shibata N; Hoshino N; Minouchi T; Yamaji A
Biol Pharm Bull; 1995 Oct; 18(10):1423-9. PubMed ID: 8593449
[TBL] [Abstract][Full Text] [Related]
26. Optimal blood concentration of cyclosporine among Iranian kidney transplant recipients.
Rostami Z; Einollahi B; Morshedi J; Teimoori M
Iran J Kidney Dis; 2012 Sep; 6(5):373-9. PubMed ID: 22976264
[TBL] [Abstract][Full Text] [Related]
27. The determination of metabolite M17 and its meaning for immunosuppressive cyclosporin therapy.
Khoschsorur G; Auer T; Lanzer G; Petritsch P; Holzer H; Tscheliessnigg KH
Angiology; 1998 Apr; 49(4):307-14. PubMed ID: 9555934
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
Ieiri I; Nakayama J; Murakami H; Hori Y; Higuchi S
Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
[TBL] [Abstract][Full Text] [Related]
29. Excellent results with high-dose mizoribine combined with cyclosporine, corticosteroid, and basiliximab in renal transplant recipients: multicenter study in Japan.
Nishimura K; Uchida K; Yuzawa K; Fukuda Y; Ichikawa Y; Akioka K; Fujisawa M; Sugitani A; Ito S; Nakatani T; Horimi T; Yoshimura N
Transplant Proc; 2012 Jan; 44(1):147-9. PubMed ID: 22310601
[TBL] [Abstract][Full Text] [Related]
30. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
[TBL] [Abstract][Full Text] [Related]
31. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
[TBL] [Abstract][Full Text] [Related]
32. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
[TBL] [Abstract][Full Text] [Related]
33. The measurement of whole blood pre-treatment cyclosporine A: metabolite ratios predicts the onset of renal dysfunction in recipients of allogeneic stem cell transplantation.
Stephens E; Bolderson I; Clark B; Kinsey S; Gooi HC; Cook G
Ann Clin Biochem; 2006 Sep; 43(Pt 5):382-8. PubMed ID: 17022881
[TBL] [Abstract][Full Text] [Related]
34. The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients.
Ferraresso M; Turolo S; Belinghieri M; Tirelli AS; Grillo P; Groppali E; Edefonti A; Ghio L
Pediatr Transplant; 2012 Sep; 16(6):658-63. PubMed ID: 22765024
[TBL] [Abstract][Full Text] [Related]
35. Optimal cyclosporine therapy--an Indian experience.
Raj DS; Somiah S; Mani K
J Assoc Physicians India; 1996 Jan; 44(1):34-6. PubMed ID: 8773092
[TBL] [Abstract][Full Text] [Related]
36. Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience.
Zakliczyński M; Szewczyk M; Zakliczyńska H; Zembala M
Ann Transplant; 2005; 10(2):38-45. PubMed ID: 16218032
[TBL] [Abstract][Full Text] [Related]
37. Cimetidine or ranitidine in renal transplant patients receiving cyclosporine.
Barri YM; Ramos EL; Balagtas RS; Peterson JC; Karlix JL
Clin Transplant; 1996 Feb; 10(1 Pt 1):34-8. PubMed ID: 8652895
[TBL] [Abstract][Full Text] [Related]
38. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
Waid T;
Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
[TBL] [Abstract][Full Text] [Related]
40. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation.
Glanville AR; Morton JM; Aboyoun CL; Plit ML; Malouf MA
J Heart Lung Transplant; 2004 Oct; 23(10):1170-4. PubMed ID: 15477111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
